SLC17A4 Inhibitors

Chemical inhibitors of SLC17A4 operate by impeding the protein's ability to transport organic anions across cell membranes. Probenecid, for instance, is known for its competitive inhibition at the transport sites of anion transporters, including SLC17A4. It binds to the same sites that the protein's substrates would, thus preventing SLC17A4 from carrying out its transport function. Similar in action, Sulfinpyrazone and Pyrazinoate also obstruct the reabsorption of uric acid by binding to the protein's anion binding sites, thereby impeding the protein's ability to move these molecules across cellular membranes. Benzbromarone and Losartan, although differing in their primary mechanisms, both inhibit SLC17A4 by blocking its specific interaction with urate, rendering the protein unable to fulfil its role in urate transport.

Furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) such as Indomethacin, Ibuprofen, Naproxen, and Phenylbutazone are capable of interfering with SLC17A4's function by disrupting the transport mechanism for organic anions. These NSAIDs have a dual impact on reducing inflammation and inhibiting SLC17A4, though their primary use is not as inhibitors of this protein. Diuretics like Furosemide and Bumetanide, while primarily used to inhibit sodium and chloride reabsorption, also exert an inhibitory influence on SLC17A4. They achieve this by blocking the movement of its organic anion substrates, such as urate, across the cell membrane. Salicylate, as the active metabolite of aspirin, competitively inhibits the transport of urate and other organic anions, disrupting SLC17A4's ability to transport these substrates.